Ritesh Kataria

986 total citations
26 papers, 759 citations indexed

About

Ritesh Kataria is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ritesh Kataria has authored 26 papers receiving a total of 759 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Surgery and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ritesh Kataria's work include Bladder and Urothelial Cancer Treatments (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Urinary and Genital Oncology Studies (7 papers). Ritesh Kataria is often cited by papers focused on Bladder and Urothelial Cancer Treatments (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Urinary and Genital Oncology Studies (7 papers). Ritesh Kataria collaborates with scholars based in United States, Japan and Germany. Ritesh Kataria's co-authors include William F. Regine, Jeanette Linder, Joseph E. Gaugler, Charles W. Given, Vincent C.O. Njar, Venkatesh Handratta, Angela Brodie, Nader Hanna, Yun Qiu and Tadas S. Vasaitis and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Medicinal Chemistry and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Ritesh Kataria

25 papers receiving 737 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ritesh Kataria 272 188 167 165 110 26 759
Dinorah Martinez‐Tyson 443 1.6× 97 0.5× 214 1.3× 57 0.3× 172 1.6× 19 997
Howard I. Scher 481 1.8× 118 0.6× 341 2.0× 106 0.6× 182 1.7× 17 961
Jimmy Hwang 272 1.0× 50 0.3× 111 0.7× 87 0.5× 95 0.9× 38 882
Natalio Walach 362 1.3× 154 0.8× 110 0.7× 137 0.8× 89 0.8× 47 719
Inge R. Konings 453 1.7× 89 0.5× 220 1.3× 33 0.2× 115 1.0× 42 1.0k
Mark Powell 720 2.6× 187 1.0× 411 2.5× 91 0.6× 454 4.1× 52 1.7k
Weng Ng 655 2.4× 153 0.8× 181 1.1× 106 0.6× 199 1.8× 73 1.1k
Charlene Thomas 328 1.2× 75 0.4× 278 1.7× 28 0.2× 112 1.0× 94 926
Beatriz Castelo 368 1.4× 68 0.4× 110 0.7× 52 0.3× 82 0.7× 50 682
Marian B. E. Menke‐Pluijmers 342 1.3× 367 2.0× 93 0.6× 116 0.7× 112 1.0× 47 1.0k

Countries citing papers authored by Ritesh Kataria

Since Specialization
Citations

This map shows the geographic impact of Ritesh Kataria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ritesh Kataria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ritesh Kataria more than expected).

Fields of papers citing papers by Ritesh Kataria

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ritesh Kataria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ritesh Kataria. The network helps show where Ritesh Kataria may publish in the future.

Co-authorship network of co-authors of Ritesh Kataria

This figure shows the co-authorship network connecting the top 25 collaborators of Ritesh Kataria. A scholar is included among the top collaborators of Ritesh Kataria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ritesh Kataria. Ritesh Kataria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Çiçin, İrfan, Elizabeth R. Plimack, Howard Gurney, et al.. (2024). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study. BMC Cancer. 23(S1). 1256–1256. 10 indexed citations
3.
Necchi, Andrea, Michiel S. van der Heijden, Avivit Peer, et al.. (2024). Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study. BMC Cancer. 23(S1). 1252–1252. 6 indexed citations
4.
Friedlander, Terence W., Matthew I. Milowsky, Peter H. O’Donnell, et al.. (2023). Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.. Journal of Clinical Oncology. 41(16_suppl). 4568–4568. 5 indexed citations
5.
6.
Hoimes, Christopher, Yohann Loriot, Jens Bedke, et al.. (2023). Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304.. Journal of Clinical Oncology. 41(6_suppl). TPS588–TPS588. 13 indexed citations
7.
Heijden, Michiel Simon Van Der, Shilpa Gupta, Matt D. Galsky, et al.. (2022). Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress).. Journal of Clinical Oncology. 40(6_suppl). TPS589–TPS589. 24 indexed citations
8.
Galsky, Matthew D., Christopher Hoimes, Andrea Necchi, et al.. (2021). Perioperative Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncology. 17(24). 3137–3150. 38 indexed citations
9.
Friedlander, Terence W., Matthew I. Milowsky, Mehmet Asım Bilen, et al.. (2021). Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).. Journal of Clinical Oncology. 39(15_suppl). 4528–4528. 39 indexed citations
10.
Hoimes, Christopher, Jens Bedke, Yohann Loriot, et al.. (2021). KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 39(15_suppl). TPS4587–TPS4587. 29 indexed citations
11.
12.
Sharma, Padmanee, Luc Dirix, Filip De Vos, et al.. (2018). Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology. 36(4_suppl). 470–470. 20 indexed citations
13.
DiBiase, Steven J., Arif Hussain, Ritesh Kataria, et al.. (2010). Long-Term Results of a Prospective, Phase II Study of Long-Term Androgen Ablation, Pelvic Radiotherapy, Brachytherapy Boost, and Adjuvant Docetaxel in Patients With High-Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 81(3). 732–736. 10 indexed citations
14.
Gaugler, Joseph E., et al.. (2008). The Proliferation of Primary Cancer Caregiving Stress to Secondary Stress. Cancer Nursing. 31(2). 116–123. 30 indexed citations
15.
Gaugler, Joseph E., et al.. (2007). Work, gender, and stress in family cancer caregiving. Supportive Care in Cancer. 16(4). 347–357. 49 indexed citations
16.
Regine, William F., Nader Hanna, Michael Garofalo, et al.. (2007). Low-Dose Radiotherapy as a Chemopotentiator of Gemcitabine in Tumors of the Pancreas or Small Bowel: A Phase I Study Exploring a New Treatment Paradigm. International Journal of Radiation Oncology*Biology*Physics. 68(1). 172–177. 35 indexed citations
17.
Gaugler, Joseph E., Nader Hanna, Jeanette Linder, et al.. (2005). Cancer caregiving and subjective stress: a multi-site, multi-dimensional analysis. Psycho-Oncology. 14(9). 771–785. 120 indexed citations
18.
Handratta, Venkatesh, Tadas S. Vasaitis, Vincent C.O. Njar, et al.. (2005). Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens:  Synthesis, in Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft Model. Journal of Medicinal Chemistry. 48(8). 2972–2984. 209 indexed citations
19.
Handratta, Venkatesh, Danijela Jelovac, Brian J. Long, et al.. (2004). Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. The Journal of Steroid Biochemistry and Molecular Biology. 92(3). 155–165. 19 indexed citations
20.
DiBiase, Steven J., Nancy A. Dawson, Michael J. Naslund, et al.. (2004). Phase II study of combined external beam radiation therapy (EBRT), brachytherapy (PB), total androgen suppression (TAS), and adjuvant docetaxel (AD) in poor-risk, localized prostate cancer (PCa). Journal of Clinical Oncology. 22(14_suppl). 4764–4764. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dinorah Martinez‐Tyson Breakdown of academic impact, for papers by Howard I. Scher Breakdown of academic impact, for papers by Jimmy Hwang Breakdown of academic impact, for papers by Natalio Walach Breakdown of academic impact, for papers by Inge R. Konings Breakdown of academic impact, for papers by Mark Powell Breakdown of academic impact, for papers by Weng Ng Breakdown of academic impact, for papers by Charlene Thomas Breakdown of academic impact, for papers by Beatriz Castelo Breakdown of academic impact, for papers by Marian B. E. Menke‐Pluijmers
Rankless by CCL
2026